Location of Repository

Low-cumulative dose isotretinoin treatment in mild to moderate acne: efficacy in achieving stable remission

By A. Borghi, L. Mantovani, S. Minghetti, S. Giari, A. Virgili and V. Bettoli


Background: Aimed at the reduction of post-treatment relapse of severe acne, the cumulative dose of oral isotretinoin should be ≥ 120 mg/kg. However, data on the appropriate oral isotretinoin treatment regimen in mild and moderate acne are lacking. Objective: The purpose of this study was to determine the efficacy of an isotretinoin-sparing protocol in inducing permanent remission of mild and moderate acne. Methods: In this open, prospective, noncomparative study 150 patients affected with mild to moderate acne were treated with isotretinoin until complete recovery and for a further month of treatment, independently of the total cumulative dose reached. Patients then underwent a 1-year maintenance therapy with adapalene 0.1% cream. Patients were followed up for a further year, without any treatment. Results: 139 patients completed the study. Overall, patients received a mean of 80.92 mg/kg cumulative dose of isotretinoin. In the 2-year follow-up, relapse only appeared in 13 patients (9.35%). Conclusion: Comparing our findings with published data, this isotretinoin-sparing regimen was shown to be effective in inducing stable remission and preventing acne relapses in patients with mild to moderate acne. Low cumulative dose regimens may potentially lead to a lower incidence of side effects and to lower costs than higher doses

Topics: mild and moderate acne, oral isotretinoin, low-dose therapy, relapse
Year: 2011
DOI identifier: 10.1111/j.1468-3083.2010.03933.x
OAI identifier: oai:iris.unife.it:11392/1431326
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/11392/14... (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.